Partnering Opportunities
Our alliances with leading pharmaceutical and biotechnology companies have served to provide a significant near-term and long-term source of funding for Sunesis' research and development efforts, as well as important validation for the company's capabilities.
Currently, we maintain global commercial rights to both vosaroxin and SNS-314. As we focus our internal efforts on the advancement of vosaroxin to market, we are seeking a co-development and co-promotional partner to provide additional revenue and resources, share in both the risks and the potential upside, and enable broader development of vosaroxin in other solid and hematologic cancer indications.
Sunesis is developing vosaroxin in both AML and ovarian cancer.
Be a part of the team that will revolutionize the discovery and development of oncology treatment.
Copyright © Sunesis Pharmaceuticals, Inc. 2007. All Rights Reserved.